yellow fever vaccine (live)

Yellow fever vaccine (YF17D) is a live-attenuated viral vaccine developed in the 1930s by Max Theiler and colleagues at the Rockefeller Foundation, for which Theiler was awarded the Nobel Prize in 1951. The vaccine is derived from the wild-type Asibi strain of the yellow fever virus (YFV) through serial passage in chicken embryo tissue. It is highly effective, with a single dose providing long-lasting, often lifelong, protective immunity in over 99% of recipients. YF17D acts by replicating sub-clinically in the host and activating multiple Toll-like receptors (TLRs 2, 7, 8, and 9) as well as cytosolic sensors (RIG-I and MDA5) on dendritic cells, triggering a robust, polyfunctional innate and adaptive immune response characterized by neutralizing antibodies and antigen-specific T cells. It is marketed globally under brand names such as Stamaril and YF-VAX, and is also widely utilized as a viral vector platform for other chimeric vaccines, such as those against Japanese encephalitis and dengue.

Brand names

ArilvaxBerna-YFFlavimunStamarilYF-VAX

Other names

17D17D-20417D-21317DDYF-17DYF17DYF 17Dlive attenuated yellow fever vaccineyellow fever vaccineyellow fever vaccine (live)yellow fever vaccine liveyellow fever vaccine, live